Sedaghat Mohammadreza, Bagheri Mansooreh, Ghavami Shahri, Bamdad Shahram
Mashad Ophthalmology Research Center, Khatam-Alanbiya Hospital, Mashad University of Medical Sciences, Mashad, Iran.
Poostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Middle East Afr J Ophthalmol. 2015 Apr-Jun;22(2):212-9. doi: 10.4103/0974-9233.151877.
To evaluate changes in corneal topography and biomechanical properties after collagen cross-linking (CXL) for progressive keratoconus.
Collagen cross-linking was performed on 97 eyes. We assessed uncorrected visual acuity (UCVA) and best corrected visual acuity (BCVA). Corneal topography indices were evaluated using placido disc topography, scanning slit anterior topography (Orbscan II), and rotating Scheimpflug topography (Pentacam). Specular microscopy and corneal biomechanics were evaluated.
A 1-year-follow-up results revealed that UCVA improved from 0.31 to 0.45 and BCVA changed from 0.78 to 0.84 (P < 0.001). The mean of average keratometry value decreased from 49.62 to 47.95 D (P < 0.001). Astigmatism decreased from 4.84 to 4.24 D (P < 0.001). Apex corneal thickness decreased from 458.11 to 444.46 μm. Corneal volume decreased from 56.66 to 55.97 mm(3) (P < 0.001). Posterior best fit sphere increased from 55.50 to 46.03 mm (P = 0.025). Posterior elevation increased from 99.2 to 112.22 μm (P < 0.001). Average progressive index increased from 2.26 to 2.56 (P < 0.001). A nonsignificant decrease was observed in mean endothelial count from 2996 to 2928 cell/mm(2) (P = 0.190). Endothelial coefficient of variation (CV) increased nonsignificantly from 18.26 to 20.29 (P = 0.112). Corneal hysteresis changed from 8.18 to 8.36 (P = 0.552) and corneal resistance factor increased from 6.98 to 7.21 (P = 0.202), so these changes were not significant.
Visual acuity and K values improved after CXL. In spite of the nonsignificant increase in endothelial cell count and increase in the CV, CLX seems to be a safe treatment for keratoconus. Further studies with larger sample sizes and longer follow-up periods are recommended.
评估胶原交联(CXL)治疗进展性圆锥角膜后角膜地形图和生物力学特性的变化。
对97只眼进行了胶原交联。我们评估了裸眼视力(UCVA)和最佳矫正视力(BCVA)。使用普拉西多盘地形图、扫描裂隙前表面地形图(Orbscan II)和旋转Scheimpflug地形图(Pentacam)评估角膜地形图指数。评估了角膜内皮显微镜检查和角膜生物力学。
1年随访结果显示,UCVA从0.31提高到0.45,BCVA从0.78变为0.84(P < 0.001)。平均角膜曲率值从49.62 D降至47.95 D(P < 0.001)。散光从4.84 D降至4.24 D(P < 0.001)。角膜顶点厚度从458.11μm降至444.46μm。角膜体积从56.66 mm³降至55.97 mm³(P < 0.001)。后表面最佳拟合球径从55.50 mm增至46.03 mm(P = 0.025)。后表面高度从99.2μm增至112.22μm(P < 0.001)。平均进展指数从2.26增至2.56(P < 0.001)。平均内皮细胞计数从2996个/mm²降至2928个/mm²,差异无统计学意义(P = 0.190)。内皮细胞变异系数(CV)从18.26增至20.29,差异无统计学意义(P = 0.112)。角膜滞后从8.18变为8.36(P = 0.552),角膜阻力因子从6.98增至7.21(P = 0.202),因此这些变化不显著。
CXL后视力和角膜曲率值得到改善。尽管内皮细胞计数无显著增加且CV有所升高,但CXL似乎是一种治疗圆锥角膜的安全方法。建议进行更大样本量和更长随访期的进一步研究。